LEO 153339
Alternative Names: LEO-153339Latest Information Update: 21 May 2021
At a glance
- Originator LEO Pharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 12 May 2021 Preclinical trials in Unspecified in Denmark (unspecified route)
- 12 May 2021 LEO Pharma plans a phase I trial (in volunteers) (NCT04883333) (EudraCT 2020-005748-51)